The other CNVM: A review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents

Survey of Ophthalmology

Volumn 60, Issue 3, 2015, Pages 204-215

  Adatia, Feisal A ^a,b   Luong, Micah ^b   Munro, Monique ^b   Tufail, Adnan ^c  

^a Mitchell Eye Centre   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Choroidal neovascular membrane; Macular degeneration; Pathological myopia; PEDG; Photodynamic therapy; Ranibizumab; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE; CHOROID DISEASE; CHOROIDAL NEOVASCULAR MEMBRANE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CORNEA NEOVASCULARIZATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; LASER THERMOTHERAPY; MACULAR THICKNESS; MYOPIA; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DEGENERATIVE MYOPIA; PHOTOCHEMOTHERAPY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; HUMANS; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84927710290     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2014.10.002     Document Type: Review

References (87)

1. Anantharaman G., Pawar S., Prakash J., et al. Bilateral regression of choroidal neovascularization associated with pathologic myopia following unilateral intravitreal bevacizumab injection. World J Retina Vit 2011, 1:23-26.
2. Arias L., Planas N., Prades S., et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008, 92:1035-1039.
3. Avila M.P., Weiter J.J., Jalkh A.E., et al. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984, 91:1573-1581.
4. Axer-Siegel R., Ehrlich R., Weinberger D., et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age of treatment. Am J Ophthalmol 2004, 138:602-607.
5. Baba T., Kubota-Taniai M., Kitahashi M., et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010, 94:864-870.
6. Baba T., Ohno-Matsui K., Yoshida T. Optical coherence tomography of choroidal neovascularization in high myopia. Acta Ophthalmol Scand 2002, 80:82-87.
7. Bakri S., Snyder M.R., Reid J., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007, 114:2179-2182.
8. Blinder K., Blumenkranz M., Bressler N. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003, 110:667-673.
9. Carneiro A., Falcão M., Pirraco A., et al. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res 2009, 88:522-527.
10. Chan W.M., Lai T.Y., Chan K.P. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Retina 2008, 1300-1313.
11. Chan W.M., Lai T.Y., Liu D.T., et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009, 93:150-154.
12. Chan W.M., Lai T.Y., Liu D.T., et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007, 114:2190-2196.
13. Chan W.M., Ohji M., Lai T.Y., et al. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol 2005, 89:1522-1528.
14. Chang L.K., Spaide R.F., Brue C., et al. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Acta Ophthalmol 2008, 126:951-954.
15. Cohen S., Laroche A., Leguen Y., et al. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996, 103:1240-1244.
16. Cohen S. Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia. Retina 2009, 29:1062-1066.
17. The Myopias: Basic Science and Clinical Management 1985, 7-10. Lippcott, Philadelphia, PA. B.J. Curtin (Ed.).
18. Dawson D.W., Volpert O.V., Gillis P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
19. Dayan Y.B., Levin A., Morad Y. The changing prevalence of myopia in young adults: a 13-year series of population-based prevalence surveys. Invest Ophthalmol Vis Sci 2005, 46:2760-2765.
20. Delori F.C., Goger D.G., Dorey C.K. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci 2001, 42:1855-1866.
21. Ergun E., Heinzl H., Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004, 138:434-438.
22. Gaudreault J., Fei D., Beyer J.C., et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007, 27:1260-1266.
23. Gaudreault J., Fei D., Rusit J., et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005, 46:726-733.
24. Gharbiya M., Allievi F., Mazzeo L., et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009, 147:84-93.
25. Gharbiya M., Giustolis R., Allievi F. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab-a randomized controlled trial. Am J Ophthalmol 2010, 149:458-464.
26. Grossniklaus H., Green W. Choroidal neovascularization. Am J Ophthalmol 2004, 137:496-503.
27. Grossniklaus H., Green W. Pathologic findings in pathologic myopia. Retina 1992, 12:127-133.
28. Hampton G.R., Kohen D., Bird A.C. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983, 90:923-926.
29. Hayashi K., Ohno-Matsui K., Shimada N., et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009, 247:609-618.
30. Hayashi K., Ohno-Matsui K., Teramukai S., et al. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic. Am J Ophthalmol 2009, 148:369-408.
31. Hernández-Rojas M.L., Quiroz-Mercado H., Dalma-Weiszhausz J., et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007, 27:707-712.
32. Iacono P., Parodi M., Papayannis A., et al. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia. Retina 2011, 31:1841-1847.
33. Iacono P., Parodi M., Papayannis A., et al. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization. Retina 2012, 32:1539-1546.
34. Ikuno Y., Nagai Y., Matsuda S., et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010, 149:140-146.
35. Ikuno K., Sayanagi K., Soga, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009, 147:94-100.
36. Jalkh A.E., Weiter J.J., Trempe C.L., et al. Choroidal neovascularization in degenerative myopia: Role of laser photocoagulation. Ophthalmic Surg 1987, 18:721-725.
37. Kojima A., Ohno-Matsui K., Teramukai S., et al. Estimation of visual outcome without treatment in patients with subfoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2006, 244:1474-1479.
38. Kojima A., Ohno-Matsui K., Teramukai S., et al. Factors associated with the development of chorioretinal atrophy around choroidal neovascularization in pathologic myopia. Graefes Arch Clin Exp Ophthalmol 2004, 242:114-119.
39. Konstantinidis L., Mante I., Pournaras J.A., et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009, 247:311-318.
40. Kuo J.Z., Ong F.S., Yeung L., et al. Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization. Retina 2011, 31:1835-1840.
41. Lai T., Luk F., Lam D. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization. Eye 2012, 26:1004-1011.
42. Lalloum F., Souied E., Bastujui-Garin S. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010, 3:399-406.
43. Laud K., Spaide R.F., Freund K.B., et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006, 26:960-963.
44. Mennel S., Barbazetto I., Meyer C., et al. Ocular photodynamic therapy-standard applications and new indications (part 1). Review of the literature and personal experience. Ophthalmologica 2007, 221:216-226.
45. Miller D., Singerman L. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci 2006, 86:316-325.
46. Monés J.M., Amselem L., Serrano A., et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results. Eye (Lond) 2009, 23:1275-1280.
47. Montero J.A., Ruiz-Moreno J.M. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation. Br J Ophthalmol 2003, 87:173-176.
48. Morgan I.G., Ohno-Matsui K., Saw S. Myopia. Lancet 2012, 379:1739-1748.
49. Estimated Statistics on Blindness and Vision Problems 1966, 44. National Society for the Prevention of Blindness, National Society for the Prevention of Blindness, New York.
50. Ng D., Kwok A., Chan C. Anti-vascular endothelial growth factor for myopic choroidal neovascularization. Clin Exp Ophthalmol 2012, 40:e98-e110.
51. Nguyen Q.D., Shah S., Tatlipinar S., et al. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005, 89:1368-1370.
52. Noske U.M., Schmidt-Erfurth U., Meyer C., et al. Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors. Ophthalmologe 1998, 95:814-819.
53. Ohno-Matsui K., Yoshida T., Futagami S. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003, 87:570-573.
54. Parodi M.B., Lacono P., Papayannis A., et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010, 128:437-442.
55. Qureshi F., Saeed M.U., Kamal A. Primary intravitreal ranibizumab for myopic choroidal neovascularisation. Semin Ophthalmol 2011, 26:52-54.
56. Rhéaume M.A., Sebag M. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. Can J Ophthalmol 2008, 43:565-580.
57. Rich R., Rosenfeld P., Puliafito C., et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006, 26:495-511.
58. Rotsos T., Sagoo M., daCruz L., et al. Intravitreal anti-VEGF treatment in eye with combined choroidal neovascularization and vitreomacular traction syndrome. Br J Ophthalmol 2010, 94:1205-1210.
59. Ruiz-Moreno J.M., Montero J.A., Gomez-Ulla F., et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009, 93:448-451.
60. Ruiz-Moreno J.M., Montero J.A. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010, 248:937-941.
61. Sakaguchi H., Ikuno Y., Gomi F., et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007, 91:161-165.
62. Saw S., Katz J., Schein O.D., et al. Epidemiology of myopia. Epidemiol Rev 1996, 18:175-187.
63. Schmidt-Erfurth U., Hasan T., Gragoudas E., et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994, 101:1953-1961.
64. Secrétan M., Kuhn D., Soubrane G., et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: Natural history and laser treatment. Eur J Ophthalmol 1997, 7:307-316.
65. Shahar J., Avery R.L., Heilweil G. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006, 26:262-269.
66. Shih Y.F., Ho T.C., Hsiao C.K., et al. Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study. Br J Ophthalmol 2006, 90:546-550.
67. Silva R.M., Ruiz-Moreno J.M., Nascimento J., et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008, 28:1117-1123.
68. Silva R.M., Ruiz-Moreno J.M., Rosa P. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina 2010, 30:407-412.
69. Soubrane G. Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment. Surv Ophthalmol 2008, 53:121-138.
70. Tatar O., Adam A., Shinoda K. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006, 142:95-104.
71. Tewari A., Dhalla M.S., Apte R.S. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006, 26:1093-1094.
72. Tong J.P., Chan W.M., Liu D., et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006, 141:456-462.
73. Tufail A., Narendran N., Patel P., et al. Ranibizumab in myopic choroidal neovascularization: the 12 month results from the REPAIR study. Ophthalmology 2013, 120:1944-1945.
74. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001, 108:841-852. Verteporfin in Photodynamic Therapy Study Group.
75. Virgili G., Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev 2005, (4):CD004765.
76. Voykov B., Gelisken F., Inhoffen W., et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?. Graefes Arch Clin Exp Ophthalmol 2010, 248:543-550.
77. Wakabayashi T., Ikuno Y., Gomi F., et al. Intravitreal bevacizumab vs. sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia. Am J Ophthalmol 2009, 148:591-596.
78. Wakabayashi T., Ikuno Y., Gomi F. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. Retina 2011, 31:880-886.
79. Wolf S., Balciuniene V., Laganovska G., et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 2014, 121:682-692.
80. Wong D., Li K.K. Avastin in myopic choroidal neovascularisation: Is age the limit?. Br J Ophthalmol 2008, 92:1011-1012.
81. Wu P.C., Chen Y.J. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye (Lond) 2009, 23:2042-2045.
82. Yamamoto I., Rogers A.H., Reichel E., et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol 2007, 91:157-160.
83. Yoon J., Kim Y., Lee S., et al. Prognostic factors for visual outcome after intravitreal anti-vegf injection for naïve myopic choroidal neovascularization. Retina 2012, 32:949-955.
84. Yoon J.U., Byun Y.J., Koh H.J. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. Retina 2010, 30:418-424.
85. Yoshida T., Ohno-Matsui K., Ohtake Y., et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002, 109:712-719.
86. Yoshida T., Ohno-Matsui K., Yasuzumi K. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 2003, 110:1297-1305.
87. Yu L., Liang X.H., Ferrara N. Comparing protein VEGF inhibitors: invitro biological studies. Biochem Biophys Res Commun 2011, 408:276-281.